targeted therapeutic
Recently Published Documents


TOTAL DOCUMENTS

331
(FIVE YEARS 111)

H-INDEX

35
(FIVE YEARS 5)

Author(s):  
Paola Mattiolo ◽  
Valentyna Kryklyva ◽  
Lodewijk A. Brosens ◽  
Andrea Mafficini ◽  
Rita T. Lawlor ◽  
...  

2021 ◽  
pp. clincanres.1798.2021
Author(s):  
Sai Kiran Sharma ◽  
Kyeara N. Mack ◽  
Alessandra Piersigilli ◽  
Jacob Pourat ◽  
Kimberly J. Edwards ◽  
...  

Author(s):  
Jingxian Gao ◽  
Xianli Meng ◽  
Bayin Zabu ◽  
Yi Zhang ◽  
Siqinbilig Wu ◽  
...  

Aims: To identify more effective ginsenoside for type 2 diabetes (T2D) and clarify whether the ginsenoside characterizing estrogenic multi-targeted antidiabetic effects. Study Design: Identifying more effective ginsenoside through preclinical evaluation of antidiabetic effects of representative ginsenosides with T2D rat model, and further test pharmacological mechanism underlying the potent antidiabetic effects of the ginsenoside in the same model. Place and Duration of Study: Key laboratory for Pharmacy, Inner Mongolia Medical University, March 2018 to November 2020. Methodology: Used a total of 240 female adult rats. Rat model of T2D induced by high-fat diet fed and streptozotocin. Five tapes of representative ginsenosides (Rb1, Rd, Rg3, Re, Rg1) administrated at low (20 mg/kg daily) and high (40 mg/ kg daily) doses to T2D rats with orally for 4 weeks. Detect testing indexes with biochemical, histological, Quantitative Real-Time PCR, and western blots analysis. Results: Ginsenoside Re (Re), very significantly lowered blood glucose (P<0.01), lipids (P<0.001), free fatty acid (P<0.001), and glucagon (P<0.01) levels, markedly improved impaired insulin sensitivity (P<0.01), ameliorated oxidative stress (P<0.01) and inflammation (P<0.01) in T2D rats, exhibited potent antidiabetic effects. Moreover, Re, phosphorylate serine/threonine kinase (Akt) (P<0.01) and endothelial nitric oxide synthase (eNOS) (P<0.01), up regulates B-cell lymphoma-2 (P<0.01) and insulin gene expression (P<0.01), down regulates glucagon gene expression(P<0.01), reverse impaired glucagon-like peptide 1 (P<0.01); exhibits multi-targeted effects; these effects of Re were inhibited by estrogen receptor (ER) inhibitor (ICI-182,780) (P<0.01). Functionally, the antidiabetic effects of Re were sequentially inhibited by inhibitor of ER, Akt, and eNOS, respectively (P<0.01). Conclusion: These findings, revealed a novel pharmacological property of Re that characterized in multi-targeted potent antidiabetic effects mediated by ER/Akt/eNOS/NO signaling pathway, provide the first evidence for the potential use of Re, as a multi-targeted therapeutic for T2D, particularly, a novel candidate for replacement of estrogen therapy and NO therapy in diabetes.


2021 ◽  
Vol 23 (4) ◽  
pp. 374-385
Author(s):  
Alistair Nichol ◽  
◽  
Rinaldo Bellomo ◽  
Bridget Ady ◽  
Niklas Nielsen ◽  
...  

2021 ◽  
Author(s):  
Xiang Zhang ◽  
Jianhong Chen ◽  
Fangfang Wang ◽  
Meng Zhang ◽  
Jiping Liu

Abstract Background: FOXF1 acts a crucial part to tumor initiation and progression. In this study, we aimed to analyzed FOXF1 in ovarian cancer from different databases which showed diagnosis and targeted therapeutic values.Results: The expression of FOXF1 in ovarian cancer tissue was markedly lower than that in normal tissue. Among different tumor subgroups, FOXF1 expression was conspicuously lower in higher grade stage. Additionally, FOXF1 expression and genetic variations were significantly correlated with various immune infiltrating cells. Altogether, 2594 co-expressed genes evidently pertinent to FOXF1. These genes were correlated with cell adhesion, NADH dehydrogenase complex and cytokine binding in results of enrichment analysis. In addition, FOXF1 was associated with gene networks regulated by PRKG1, miR-151, and SRF respectively. CMap analysis screened several potential small molecules for ovarian cancer treatment.Conclusions: FOXF1 has been shown to be a vital biomarker for the diagnosis of ovarian cancer and the immune infiltrating levels. The small molecules screened here supply rationale for new drug development for ovarian cancer.


Sign in / Sign up

Export Citation Format

Share Document